St Paul's Eye Unit, The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
Eye (Lond). 2009 Mar;23(3):581-5. doi: 10.1038/eye.2008.54. Epub 2008 Mar 14.
To determine the proportion of uveal melanoma patients who accept cytogenetic prognostication and to understand the reasons for their decision and the psychological impact of an adverse prognosis.
Patients treated by enucleation or local resection for uveal melanoma between 01 January 2003 and 31 December 2006 were identified and the proportion undergoing cytogenetic studies was determined. In-depth interviews of fourteen patients living near our centre were conducted to determine their reasons for accepting cytogenetic testing and their reactions to any results received.
In total 97% of 298 eligible patients with uveal melanoma treated by enucleation or local resection accepted an offer of cytogenetic prognostication. None of the patients interviewed in detail expressed any regret about having this test and there was no evidence of any harm. The main benefit perceived by patients was that they would have greater control and that screening for metastatic disease and early treatment might enhance chances of survival. This was despite counselling that prognostication, screening, and treatment are unlikely to prolong life and that the main purpose of cytogenetic studies is to allow for life-planning.
Almost all patients with uveal melanoma desire cytogenetic prognostication, although not for the reasons intended by their medical practitioners. Further studies are needed to understand patients' reactions to cytogenetic testing, so that care can be optimised.
确定接受细胞遗传学预后预测的葡萄膜黑色素瘤患者的比例,并了解他们做出决定的原因以及不良预后的心理影响。
确定了 2003 年 1 月 1 日至 2006 年 12 月 31 日期间接受眼窝切除术或局部切除术治疗的葡萄膜黑色素瘤患者,并确定了进行细胞遗传学研究的比例。对我们中心附近的 14 名患者进行了深入访谈,以确定他们接受细胞遗传学检测的原因以及对任何收到的结果的反应。
在接受眼窝切除术或局部切除术治疗的 298 名符合条件的葡萄膜黑色素瘤患者中,有 97%的患者接受了细胞遗传学预后预测的建议。在详细访谈的患者中,没有一个人对进行此项测试表示任何遗憾,也没有任何伤害的证据。患者主要认为,他们将有更大的控制能力,筛查转移疾病和早期治疗可能会提高生存机会。尽管有建议称预后预测、筛查和治疗不太可能延长生命,而且细胞遗传学研究的主要目的是为了规划生活,但他们仍持有这种观点。
几乎所有葡萄膜黑色素瘤患者都希望进行细胞遗传学预后预测,尽管这不是他们的医疗从业者所期望的原因。需要进一步研究以了解患者对细胞遗传学检测的反应,从而优化护理。